In addition, the PD‐L1 inhibitor atezolizumab combined with the VEGF inhibitor bevacizumab has been recommended as a first‐line regimen for the treatment of advanced HCC based on the results of the IMbrave150 study.8 The gene discussed is CD274; the disease is hepatocellular carcinoma.